These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36207403)

  • 61. Catastrophic ATP loss underlies a metabolic combination therapy tailored for
    Dalton KM; Lochmann TL; Floros KV; Calbert ML; Kurupi R; Stein GT; McClanaghan J; Murchie E; Egan RK; Greninger P; Dozmorov M; Ramamoorthy S; Puchalapalli M; Hu B; Shock L; Koblinski J; Glod J; Boikos SA; Benes CH; Faber AC
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762304
    [No Abstract]   [Full Text] [Related]  

  • 62. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling.
    Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W
    Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277
    [TBL] [Abstract][Full Text] [Related]  

  • 63. P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in Neuroblastoma.
    Cheng C; He T; Chen K; Cai Y; Gu Y; Pan L; Duan P; Wu Y; Wu Z
    Mol Cell Proteomics; 2023 Mar; 22(3):100504. PubMed ID: 36708875
    [TBL] [Abstract][Full Text] [Related]  

  • 64. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.
    Zhang X; Zhan S; Guan X; Zhang Y; Lu J; Yu Y; Jin Y; Yang Y; Chu P; Hong E; Yang H; Ren H; Geng D; Wang Y; Zhou P; Guo Y; Chang Y
    Cancer Sci; 2023 Jul; 114(7):2860-2870. PubMed ID: 37094904
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
    Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
    Chen Y; Tsai YH; Tseng SH
    Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
    Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
    Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
    [No Abstract]   [Full Text] [Related]  

  • 68. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
    Liu HJ; Li GL; Lei PC
    Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
    [No Abstract]   [Full Text] [Related]  

  • 69. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Potential anti-neuroblastoma agents from Juniperus oblonga.
    Qiao Y; Sunada NK; Hatada AE; Lange I; Khutsishvili M; Alizade V; Atha D; Ko'omoa-Lange DL; Borris RP
    Biochem Biophys Res Commun; 2019 Aug; 516(3):733-738. PubMed ID: 31255282
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
    Getlik M; Smil D; Zepeda-Velázquez C; Bolshan Y; Poda G; Wu H; Dong A; Kuznetsova E; Marcellus R; Senisterra G; Dombrovski L; Hajian T; Kiyota T; Schapira M; Arrowsmith CH; Brown PJ; Vedadi M; Al-Awar R
    J Med Chem; 2016 Mar; 59(6):2478-96. PubMed ID: 26958703
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.
    Szemes M; Greenhough A; Melegh Z; Malik S; Yuksel A; Catchpoole D; Gallacher K; Kollareddy M; Park JH; Malik K
    Neoplasia; 2018 Apr; 20(4):335-350. PubMed ID: 29505958
    [TBL] [Abstract][Full Text] [Related]  

  • 73. BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.
    Zhang X; Guo X; Zhuo R; Tao Y; Liang W; Yang R; Chen Y; Cao H; Jia S; Yu J; Liao X; Li X; Fang F; Li G; Wu D; Xu Y; Li Z; Pan J; Wang J
    Biochem Biophys Res Commun; 2022 May; 604():63-69. PubMed ID: 35299072
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma.
    Hald ØH; Olsen L; Gallo-Oller G; Elfman LHM; Løkke C; Kogner P; Sveinbjörnsson B; Flægstad T; Johnsen JI; Einvik C
    Oncogene; 2019 Apr; 38(15):2800-2813. PubMed ID: 30542116
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
    Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
    [No Abstract]   [Full Text] [Related]  

  • 77. Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
    Wood L; Huang M; Zeki J; Gong M; Taylor J; Shimada H; Chiu B
    J Pediatr Surg; 2021 Jul; 56(7):1199-1202. PubMed ID: 33838899
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Activation of cell migration via morphological changes in focal adhesions depends on shear stress in MYCN-amplified neuroblastoma cells.
    Hiraiwa T; Yamada TG; Miki N; Funahashi A; Hiroi N
    J R Soc Interface; 2019 Mar; 16(152):20180934. PubMed ID: 30836897
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.
    Takahashi N; Koyama S; Hasegawa S; Yamasaki M; Imai M
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4664-4672. PubMed ID: 28927789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.